500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.
Press release | 2021-03-24
Dicot initiates first studies in disease animal models
The potency drug developer Dicot has for the first time initiated studies in animals with erectile dysfunction. In earlier studies, the company's drug candidate has only been tested on healthy animals. The new studies are an important step in gaining approval for clinical trials in humans.
Read More >
The global market for treating sexual dysfunctions is annually worth more than 50 billion SEK as the underlying causes increase and the proportion of elderly increases.
There are currently no long-lasting, effective therapeutic drugs available on the market. Today's potency drugs arrived on the market over 20 years ago and have their limitations.
30% of men with diagnosed erectile dysfunction do not respond to drugs on the market today. As LIB-01 functions in a different way, it may open the possibility for these patients to receive a treatment that works.
According to early studies, Dicot's drug candidate LIB-01 has a longer lasting duration. Unlike today's potency drugs, which must be ingested shortly before planned sexual activity.
Many men suffer from both erectile dysfunction and premature ejaculation. LIB-01 is meant to work on both symptoms, something that does not exist today.
Pharmaceutical Project
The aim of this year's development work is to prepare LIB-01 for clinical studies next year.
Read More >Market
Premature ejaculation is an immature market that is expected to grow 8% over the next five-year period.
Read More >